Monitoring your patients with chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder.
• CML can present with symptoms like fatigue and organomegaly or be asymptomatic.
• Untreated CML progresses through stages with a poor prognosis.

Purpose of the Study:

• To discuss the diagnosis, progression, and molecular basis of Chronic Myeloid Leukemia (CML).
• To highlight the role of the Philadelphia chromosome and BCR-ABL fusion protein in CML pathogenesis.
• To review diagnostic and monitoring techniques for CML.

Main Methods:

• Diagnosis is suspected by elevated white blood cell count and confirmed by the Philadelphia (Ph) chromosome.
• Cytogenetic analysis visualizes the Ph chromosome and other abnormalities.
• Fluorescent in situ hybridization (FISH) detects the bcr-abl translocation.
• Polymerase chain reaction (PCR) detects minimal residual disease (MRD) by quantifying bcr-abl mRNA.

Main Results:

• The BCR-ABL fusion protein, resulting from the Ph chromosome translocation, drives CML.
• BCR-ABL is a constitutively active tyrosine kinase, leading to uncontrolled cell proliferation.
• Additional translocations can accelerate CML progression.
• The BCR-ABL fusion protein serves as a therapeutic target and a marker for MRD.

Conclusions:

• CML diagnosis relies on identifying the Philadelphia chromosome.
• Monitoring techniques like PCR are essential for tracking disease burden and recurrence.
• Effective patient care is enhanced by sensitive detection of minimal residual disease.